Abstract
Rationale
Accumulating evidence suggests that drugs acting on the glutamatergic system may represent promising novel therapeutic targets for the treatment of anxiety disorders. The stress-induced hyperthermia paradigm has been used widely to model some of the physiological symptoms associated with anxiety disorders and has produced results that are predictive of clinical efficacy. We have modified this paradigm to measure the autonomic consequences of stress induced by the fear of predation in mice.
Objective
To evaluate the efficacy of several classes of metabotropic and ionotropic glutamate receptor ligands, as well as known anxiolytics and psychotropic comparators, in attenuating predatory-stress-induced hyperthermia.
Methods
Male DBA/2 mice were implanted with radiotelemetric transmitters in the peritoneal cavity to measure stress-related increases in core body temperature, following placement in a novel cage containing soiled rat shavings.
Results
Clinically active compounds such as chlordiazepoxide (5–10 mg/kg), alprazolam (0.3–3 mg/kg), and buspirone (10–30 mg/kg) exhibited an anxiolytic profile. Assessment of glutamatergic agents indicated that the mGlu1 receptor antagonist LY456236 (10–30 mg/kg), mGlu5 receptor antagonist MPEP (10–30 mg/kg), mGlu2/3 receptor agonist LY354740 (3–10 mg/kg), mGlu2 receptor potentiator LY566332 (30 and 100 mg/kg), mGlu8 receptor agonist (S)-3,4-dicarboxyphenylglycine (30–60 mg/kg), competitive NMDA receptor antagonist LY235959 (1 mg/kg), AMPA receptor antagonist GYKI-52466 (10–20 mg/kg), and glycine transporter-1 (GlyT-1) inhibitor ALX-5407 (3–10 mg/kg) dose-dependently attenuated stress-induced hyperthermia. The AMPA receptor potentiator LY451646, iGlu5 kainate receptor antagonist LY382884, glycineB receptor partial agonist d-cycloserine, and GlyT-1 inhibitor ORG-24461 were ineffective in this model.
Conclusion
Select metabotropic and ionotropic glutamate receptor ligands exhibited an anxiolytic profile, as measured by the attenuation of stress-induced hyperthermia, and may represent viable targets for the development of pharmacological treatments for anxiety-related disorders.
Similar content being viewed by others
References
Abraham G, Solyom S, Csuzdi E, Berzsenyi P, Ling I, Tarnawa I, Hamori T, Pallagi I, Horvath K, Andrasi F, Kapus G, Harsing LG, Kiraly I, Patthy M, Horvath G (2000) New non competitive AMPA antagonists. Bioorg Med Chem 8:2127–2143
Anthony EW, Nevins ME (1993) Anxiolytic-like effects of N-methyl-d-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250:317–324
Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, Tham C-S, Tsai C, Jia J, Ashton D, Klitenick MA (2001) ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60:1414–1420
Bai F, Bergeron M, Nelson DL (2003) Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 44:1013–1021
Baldessarini RJ (1996) Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 399–430
Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW (2005) Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 66:94–99
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18:37–48
Barton ME, Peters SC, Shannon HE (2003) Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 56:17–26
Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES (2001) Positive modulation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther 298:86–102
Belzung C, Hage WE, Moindrot N, Griebel G (2001) Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 41:400–408
Bergink V, van Megen HJ, Westenberg HG (2004) Glutamate and anxiety. Eur Neuropsychopharmacol 14:175–183
Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ (1989) A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97:277–279
Bordi F, Ugolini A (1999) Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 59:55–79
Borsini F, Lecci A, Volterra G, Meli A (1989) A model to measure anticipatory anxiety in mice. Psychopharmacology (Berl) 98:207–211
Bouwknecht JA, Paylor R (2002) Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 136:489–501
Briese E, Cabanac M (1991) Stress hyperthermia: physiological arguments that it is a fever. Physiol Behav 49:1153–1157
Brodkin J, Busse C, Sukoff SJ, Varney MA (2002) Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73:359–366
Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75–82
Carvalho-Netto EF, Nunes-de-Souza RL (2004) Use of the elevated T-maze to study anxiety in mice. Behav Brain Res 148:119–132
Delle-Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis G, Zibellini M (1995) Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 15:12–19
Dielenberg RA, Carrive P, McGregor IS (2001) The cardiovascular and behavioral response to cat odor in rats: unconditioned and conditioned effects. Brain Res 897:228–237
Dunn RW, Corbett R, Fielding S (1989) Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 169:1–10
Fanselow MS, Kim JJ (1994) Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist d,l-2-amino-5-phosphonovaleric acid to the basolateral amygdala. Behav Neurosci 108:210–212
Fendt M, Schmid S (2002) Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci 15:1535–1541
Fricchione G (2004) Generalized anxiety disorder. N Engl J Med 351:675–685
Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493–1503
Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, Ballenger JC, Fyer AJ (1999) The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427–435
Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss–Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berl) 120:57–66
Grillon C, Cordova J, Levine LR, Morgan CA (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 168:446–454
Gudex C (1991) Adverse effects of benzodiazepines. Soc Sci Med 33:587–596
Harsing LG, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811–825
Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651–660
Heyden JAM, Zethof TJJ, Olivier B (1997) Stress-induced hyperthermia in singly housed mice. Physiol Behav 62:463–470
Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984–997, 979
Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179:271–283
Karcz-Kubicha M, Jessa M, Nazar M, Plaznik A, Hartmann S, Parsons CG, Danysz W (1997) Anxiolytic activity of glycine-B antagonists and partial agonists: no relation to intrinsic activity in the patch clamp. Neuropharmacology 36:1355–1367
Kehne JH, McCloskey TC, Baron BM, Chi EM, Harrison BL, Whitten JP, Palfreyman MG (1991) NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur J Pharmacol 193:283–292
Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ (2003) The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586–7591
Klodzinska A, Chojnacka-Wojcik E (2000) Anticonflict effect of the glycineB receptor partial agonist, d-cycloserine, in rats. Pharmacological analysis. Psychopharmacology (Berl) 152:224–228
Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A (1999) Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptor agonist in animal models. Neuropharmacology 38:1831–1839
Kotlinska J, Liljequist S (1998) The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav 60:119–124
Lanthorn TH (1994) d-Cycloserine: agonist turned antagonist. Amino Acids 6:247–260
Li L, Tomlinson R, Wang Y, Tsui H-CT, Chamberlain M-J, Johnson MP, Baez M, Vannieuwenhze MS, Zia-Ebrahimi M, Hong EJ, Schkeryantz JM, Monn JA, Porter WJ, Baker SR, Owton WM, Clark BP, Kingston AE (2002) A novel series of potent and selective non-competitive antagonists of metabotropic glutamate receptor 1. Neuropharmacology 43:295
Linden A-M, Johnson BG, Peters SC, Shannon HE, Tian M, Wang Y, Yu JL, Koster A, Baez M, Schoepp DD (2002) Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43:251–259
Linden A-M, Bergeron M, Baez M, Schoepp DD (2003) Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology 45:473–483
Linden A-M, Greene SJ, Bergeron M, Schoepp DD (2004) Anxiolytic activity of the mGlu2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29:502–513
Marazziti D, di Muro A, Castrogiovanni P (1992) Psychological stress and body temperature changes in humans. Physiol Behav 52:393–395
Marek GJ (2004) Metabotropic glutamate 2/3 receptors as drug targets. Curr Opin Pharmacol 4:18–22
Merali Z, Levac C, Anisman H (2003) Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biol Psychiatry 54:552–565
Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528–537
Monohan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) Characterization of a [3H]glycine recognition site as a modulatory site of the N-methyl-d-aspartate receptor complex. J Neurochem 53:370–375
Olivier B, Zethof T, Pattij T, van Boogaert M, van Oorschot R, Leahy C, Oosting R, Bouwknecht A, Veening J, van der Gugten J, Groenink L (2003) Stress-induced hyperthermia and anxiety: pharmacological validation. Eur J Pharmacol 463:117–132
O'Neill MJ, Bond A, Ornstein PL, Ward MA, Hicks CA, Hoo K, Bleakman D, Lodge D (1998) Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 37:1211–1222
Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523–579
Popoli M, Gennarelli M, Racagni G (2002) Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord 4:166–182
Quirk JC, Nisenbaum ES (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255–282
Sarro G, Gratteri S, Naccari F, Pasculli MP, Sarro A (2000) Influence of d-cycloserine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy Res 40:109–121
Schmitt U, Walkhofer S, Weigelt T, Hiemke C (2002) Free-choice ethanol consumption under the influence of GABAergic drugs in rats. Alcohol Clin Exp Res 26:457–462
Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12–20
Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189–197
Shekhar A, Keim SR (2000) LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39:1139–1146
Spooren WPJM, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267–1275
Spooren WPJM, Schoeffter P, Gasparini F, Kuhn R, Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP, and NKP608). Eur J Pharmacol 435:161–170
Spowart-Manning L, Staay FJ (2004) The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 151:37–46
Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE (2001) (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 40:311–318
Vanover KE, Suruki M, Robledo S, Huber M, Wieland S, Lan NC, Gee KW, Wood PL, Carter RB (1999) Positive allosteric modulators of the GABAA receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology (Berl) 141:77–82
Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, Parker EM, Hunter JC, Higgins GA, Reggiani A, Bertorelli R (2005) The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 179:207–217
Zethof TJJ, Heyden JAM, Tolboom JTBM, Olivier B (1995) Stress-induced hyperthermia as a putative anxiety model. Eur J Pharmacol 294:125–135
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rorick-Kehn, L.M., Hart, J.C. & McKinzie, D.L. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology 183, 226–240 (2005). https://doi.org/10.1007/s00213-005-0169-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0169-2